share_log

BioVie | 8-K/A: Current report (Amendment)

BioVie | 8-K/A: Current report (Amendment)

BioVie | 8-K/A：重大事件(修正)
美股SEC公告 ·  2024/09/25 04:51

Moomoo AI 已提取核心訊息

BioVie Inc., a Nevada-based biopharmaceutical company, has filed an amended Form 8-K/A with the Securities and Exchange Commission (SEC) on September 24, 2024. The amendment pertains to a previously filed report regarding the company's entry into a placement agent agreement with ThinkEquity LLC. This agreement is in connection with the issuance and sale of up to 1,960,800 shares of BioVie's class A common stock at $1.53 per share and/or pre-funded warrants to purchase common stock at $1.5299 per warrant, along with common stock purchase warrants to purchase an equal number of shares. The amendment was filed to include an amended Exhibit 5.1, which is the legal opinion of Fennemore Craig, P.C. No other changes were made to the original Form 8-K. The exhibits attached to the amendment include forms of the pre-funded and common warrants, the placement agent's warrant agreement, legal opinions, and consents from legal firms, as well as press releases dated September 23, 2024.
BioVie Inc., a Nevada-based biopharmaceutical company, has filed an amended Form 8-K/A with the Securities and Exchange Commission (SEC) on September 24, 2024. The amendment pertains to a previously filed report regarding the company's entry into a placement agent agreement with ThinkEquity LLC. This agreement is in connection with the issuance and sale of up to 1,960,800 shares of BioVie's class A common stock at $1.53 per share and/or pre-funded warrants to purchase common stock at $1.5299 per warrant, along with common stock purchase warrants to purchase an equal number of shares. The amendment was filed to include an amended Exhibit 5.1, which is the legal opinion of Fennemore Craig, P.C. No other changes were made to the original Form 8-K. The exhibits attached to the amendment include forms of the pre-funded and common warrants, the placement agent's warrant agreement, legal opinions, and consents from legal firms, as well as press releases dated September 23, 2024.
biovie公司是一家總部位於內華達州的生物製藥公司，於2024年9月24日向證券交易委員會（SEC）提交了修訂後的8-K/A表格。修訂涉及公司與ThinkEquity LLC簽訂的配售代理協議，該協議涉及以每股1.53美元發行和銷售高達1,960,800股biovie公司A類普通股的安排，以及以1.5299美元每份認股權證預先融資的發行和銷售，以及購買相同數量股份的普通股認股權證。修訂提交的內容包括修訂後的附件5.1，即Fennemore Craig, P.C.的法律意見。原8-K表格未作其他更改。修訂的附件包括預融資和普通權證表格，配售代理的權證協議，法律意見，法律公司同意書，以及日期爲2024年9月23日的新聞發佈。
biovie公司是一家總部位於內華達州的生物製藥公司，於2024年9月24日向證券交易委員會（SEC）提交了修訂後的8-K/A表格。修訂涉及公司與ThinkEquity LLC簽訂的配售代理協議，該協議涉及以每股1.53美元發行和銷售高達1,960,800股biovie公司A類普通股的安排，以及以1.5299美元每份認股權證預先融資的發行和銷售，以及購買相同數量股份的普通股認股權證。修訂提交的內容包括修訂後的附件5.1，即Fennemore Craig, P.C.的法律意見。原8-K表格未作其他更改。修訂的附件包括預融資和普通權證表格，配售代理的權證協議，法律意見，法律公司同意書，以及日期爲2024年9月23日的新聞發佈。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間